Secretory leukocyte protease inhibitor expression in various types of gastritis: A specific role of Helicobacter pylori infection

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 3, 2006, Pages 277-282

  Hritz, Istvan ^a   Kuester, Doerthe ^b   Vieth, Michael ^b   Herszenyi, Laszlo ^a   Stolte, Manfred ^c   Roessner, Albert ^b   Tulassay, Zsolt ^a   Wex, Thomas ^a,b   Malfertheiner, Peter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

Autoimmune gastritis; Gastritis; Helicobacter pylori; Non steroidal anti inflammatory drug; Secretory leukocyte protease inhibitor

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ANALYSIS OF VARIANCE; ARTICLE; AUTOIMMUNE DISEASE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; GASTRITIS; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STOMACH ANTRUM; STOMACH EPITHELIUM; STOMACH MUCOSA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; PYLORIC ANTRUM; RETROSPECTIVE STUDIES; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR;

EID: 33644590993     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200603000-00008     Document Type: Article

References (29)

1. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161-1181.
2. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-1131.
3. Asaka M, Takeda H, Sugiyama T, Kato M. What role does Helicobacter pylori play in gastric cancer? Gastroenterology 1997; 113 (suppl. 6):S56-S60.
4. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med 1997; 337:1441-1448.
5. Müller H, Volkholz H, Stolte M. Healing of lymphocytic gastritis by eradication of Helicobacter pylori. Digestion 2001; 63:14-19.
6. Haot J, Hamichi L, Wallez L, Mainguet P. Lymphocytic gastritis: a newly described entity: a retrospective endoscopic and histological study. Gut 1998; 29:1258-1264.
7. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269:15957-15960.
8. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996; 64:4520-4524.
9. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting antihuman immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96:456-464.
10. Chattopadhyay A, Gray LR, Patton LL, Caplan DJ, Slade GD, Tien HC, et al. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun 2004; 72:1956-1963.
11. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem 2002; 277:29999-30009.
12. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 2000; 6: 1147-1153.
13. Wang X, Li X, Xu L, Zhan Y, Yaish-Ohad S, Erhardt JA, et al. Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. Mol Pharmacol 2003; 64:833-840.
14. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003; 100:5778-5782.
15. Greene CM, McElvaney NG, O'Neill SJ, Taggart CC. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004; 72:3684-3687.
16. Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, et al. Inhibition of NF-kappaB activation and augmentation of Ikappa Bbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999; 154:239-247.
17. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, et al. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 2004; 172:4535-4544.
18. Song X, Zeng L, Jin W, Thompson J, Mizel DE, Lei K, et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999; 190:535-542.
19. Sallenave JM. The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res 2000; 1:87-92.
20. Duits LA, Tjabringa GS, Aarts NJ, van't Wout JW, Hiemstra PS, Nibbering PH, et al. Plasma secretory leukocyte protease inhibitor in febrile patients. Clin Microbiol Infect 2003; 9:605-613.
21. Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, Lowry SF, et al. Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med 2000; 28:1276-1282.
22. Wex T, Treiber G, Nilius M, Vieth M, Roessner A, Malfertheiner P. Helicobacter pylori-mediated gastritis induces local downregulation of secretory leukocyte protease inhibitor in the antrum. Infect Immun 2004; 72:2383-2385.
23. Wex T, Sokic-Milutinovic A, Todorovic V, Bjelovic M, Milosavljevic T, Pesko P, et al. Down-regulation of secretory leukocyte protease inhibitor expression in gastric mucosa is a general phenomenon in Helicobacter pylori-related gastroduodenal diseases. Dig Dis 2004; 22:390-395.
24. Wex T, Ye S, Treiber G, Vieth M, Roessner A, Malfertheiner P. H. pylori infection, but not low-dose aspirin, results in a local reduction of the secretory leukocyte protease inhibitor (SLPI) in gastroduodenal mucosa. Helicobacter 2006; 11:31-38.
25. Dixon MF, Wyatt JI, Burke DA, Rathbone BJ. Lymphocytic gastritis: relationship to Campylobacter pylori infection. J Pathol 1988; 154: 125-132.
26. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, et al. Conversion of proepithelin to epithelia's: roles of SLPI and elastase in host defense and wound repair. Cell 2002; 111:867-878.
27. Taggart CC, Greene CM, McElvaney NG, O'Neill S. Secretory leucoprotease inhibitor prevents LPS-induced Ikappa B alpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002; 277:33648-33653.
28. Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr Pharm Des 2004; 10:2891-2905.
29. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996; 64:4520-4524.